Sign in or create an account to add this stock to your watchlist.
About Akebia Therapeutics (NASDAQ:AKBA)
Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat which is an oral therapy in a phase three development that has the potential to set a new standard of care in treatment of anemia associated with chronic kidney disease. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098
Debt
Debt-to-Equity RatioN/A
Current Ratio2.89
Quick Ratio2.89
Price-To-Earnings
Trailing P/E Ratio-5.82
Forward P/E Ratio-4.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.98 million
Price / Sales3.29
Cash FlowN/A
Price / CashN/A
Book Value$3.46 per share
Price / Book2.98
Profitability
EPS (Most Recent Fiscal Year)($1.77)
Net Income$-76,910,000.00
Net Margins-27.48%
Return on Equity-47.15%
Return on Assets-15.05%
Miscellaneous
Employees114
Outstanding Shares56,880,000
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc. (NASDAQ:AKBA) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.01. The biopharmaceutical company had revenue of $45.93 million for the quarter, compared to the consensus estimate of $47.80 million. Akebia Therapeutics had a negative return on equity of 47.15% and a negative net margin of 27.48%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
6 Wall Street analysts have issued 1-year price objectives for Akebia Therapeutics' stock. Their forecasts range from $17.00 to $30.00. On average, they anticipate Akebia Therapeutics' share price to reach $24.20 in the next year. View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/14/2018)
- 2. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Xencor (XNCR), Corcept Therapeutics (CORT), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK), Spectrum Pharmaceuticals (SPPI), Insmed (INSM), Akcea Therapeutics (AKCA), Puma Biotechnology (PBYI), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT) and Enanta Pharmaceuticals (ENTA).
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- John P. Butler, President, CEO & Director
- Gavin T. Malenfant, Vice President-Operations
- Jason A. Amello, CFO, Treasure, SVP & Principal Accounting Officer
- Rita Jain, Chief Medical Officer & Senior Vice President
- Michel Dahan, Chief Business Officer & Senior Vice President
Has Akebia Therapeutics been receiving favorable news coverage?
Press coverage about AKBA stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.16 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.82 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Akebia Therapeutics' major shareholders?
Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.56%), Eagle Asset Management Inc. (4.79%), Millennium Management LLC (1.16%), DAFNA Capital Management LLC (1.07%), Northern Trust Corp (0.91%) and American Century Companies Inc. (0.88%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.
Which institutional investors are selling Akebia Therapeutics stock?
AKBA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Wells Fargo & Company MN and Citigroup Inc.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.
Which institutional investors are buying Akebia Therapeutics stock?
AKBA stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., DAFNA Capital Management LLC, BlackRock Inc., CVI Holdings LLC, Stanley Laman Group Ltd., PNC Financial Services Group Inc., Point72 Asset Management L.P. and Spark Investment Management LLC. View Insider Buying and Selling for Akebia Therapeutics.
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $10.30.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $588.74 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akebia Therapeutics (NASDAQ:AKBA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Their average twelve-month price target is $24.20, suggesting that the stock has a possible upside of 134.95%. The high price target for AKBA is $30.00 and the low price target for AKBA is $17.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.89 | 2.89 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.20 | $22.7778 | $22.7778 | $21.2857 |
| Price Target Upside: | 134.95% upside | 68.47% upside | 57.63% upside | 49.48% upside |
Akebia Therapeutics (NASDAQ:AKBA) Consensus Price Target History
Akebia Therapeutics (NASDAQ:AKBA) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Akebia Therapeutics (NASDAQ:AKBA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Akebia Therapeutics (NASDAQ AKBA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 75.66%
Akebia Therapeutics (NASDAQ AKBA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/15/2018 | Duane Nash | Director | Sell | 1,000 | $14.62 | $14,620.00 | |  |
| 10/2/2017 | Duane Nash | Director | Sell | 1,188 | $19.64 | $23,332.32 | | |
| 10/2/2017 | Michel Dahan | SVP | Sell | 1,398 | $19.64 | $27,456.72 | | |
| 9/28/2017 | Michel Dahan | SVP | Sell | 5,000 | $19.30 | $96,500.00 | 97,224 | |
| 8/15/2017 | Michel Dahan | SVP | Sell | 5,000 | $15.00 | $75,000.00 | 102,224 | |
| 7/5/2017 | Muneer A Satter | Director | Buy | 1,034,482 | $14.50 | $14,999,989.00 | | |
| 7/3/2017 | Duane Nash | Director | Sell | 990 | $14.27 | $14,127.30 | 23,687 | |
| 7/3/2017 | Nicole R. Hadas | SVP | Sell | 1,554 | $14.26 | $22,160.04 | | |
| 4/3/2017 | Duane Nash | Director | Sell | 991 | $9.20 | $9,117.20 | 24,677 | |
| 4/3/2017 | Nicole R Hadas | SVP | Sell | 1,556 | $9.18 | $14,284.08 | 109,856 | |
| 1/3/2017 | Duane Nash | Director | Sell | 1,980 | $10.46 | $20,710.80 | 25,668 | |
| 1/1/2017 | Nicole R. Hadas | SVP | Sell | 1,810 | $10.49 | $18,986.90 | | |
| 7/6/2016 | Duane Nash | Director | Sell | 1,980 | $7.48 | $14,810.40 | 29,629 | |
| 7/5/2016 | Nicole R. Hadas | SVP | Sell | 1,557 | $7.47 | $11,630.79 | | |
| 4/4/2016 | Michel Dahan | SVP | Sell | 1,401 | $9.41 | $13,183.41 | 74,956 | |
| 10/2/2015 | Nicole R Hadas | SVP | Sell | 1,484 | $8.67 | $12,866.28 | 65,260 | |
| 7/2/2015 | Nicole R Hadas | SVP | Sell | 1,484 | $9.54 | $14,157.36 | | |
| 4/22/2015 | Muneer A Satter | Director | Buy | 420,000 | $8.25 | $3,465,000.00 | | |
| 4/2/2015 | Nicole R Hadas | SVP | Sell | 1,483 | $9.09 | $13,480.47 | | |
| 1/2/2015 | Nicole R Hadas | VP | Sell | 1,715 | $11.46 | $19,653.90 | | |
| 12/29/2014 | John P Butler | CEO | Buy | 1,000 | $11.57 | $11,570.00 | | |
| 12/26/2014 | Duane Nash | Director | Sell | 11,933 | $11.23 | $134,007.59 | | |
| 12/22/2014 | John P Butler | CEO | Buy | 1,000 | $11.92 | $11,920.00 | | |
| 12/15/2014 | John P Butler | CEO | Buy | 1,000 | $11.34 | $11,340.00 | | |
| 12/2/2014 | Ronald C Renaud Jr | Director | Buy | 5,000 | $11.92 | $59,600.00 | | |
| 11/26/2014 | Jason Amello | CFO | Buy | 1,000 | $13.22 | $13,220.00 | | |
| 11/25/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.18 | $65,900.00 | | |
| 11/24/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.88 | $69,400.00 | | |
| 11/21/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.73 | $73,650.00 | | |
| 11/20/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.70 | $73,500.00 | | |
| 11/19/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.85 | $74,250.00 | | |
| 11/18/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.84 | $69,200.00 | | |
| 11/17/2014 | Muneer A Satter | Director | Buy | 5,000 | $12.94 | $64,700.00 | | |
| 11/14/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.91 | $59,550.00 | | |
| 11/13/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.56 | $57,800.00 | | |
| 11/12/2014 | John P Butler | CEO | Buy | 1,000 | $10.31 | $10,310.00 | | |
| 11/12/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.90 | $59,500.00 | | |
| 3/25/2014 | A/S Novo | Insider | Buy | 182,590 | $17.00 | $3,104,030.00 | | |
| 3/25/2014 | Jason Amello | CFO | Buy | 4,000 | $17.00 | $68,000.00 | | |
| 3/25/2014 | John P Butler | CEO | Buy | 13,850 | $17.00 | $235,450.00 | | |
| 3/25/2014 | Muneer A Satter | Director | Buy | 91,295 | $17.00 | $1,552,015.00 | | |
(Data available from 1/1/2013 forward)
Akebia Therapeutics (NASDAQ AKBA) News Headlines
| Source: |
|
Akebia Therapeutics (NASDAQ:AKBA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akebia Therapeutics (NASDAQ:AKBA) Income Statement, Balance Sheet and Cash Flow Statement
Akebia Therapeutics (NASDAQ AKBA) Stock Chart for Saturday, May, 26, 2018
Loading chart…
